The ASX is expected to open slightly higher on Friday as reports suggest the US debt ceiling talks could be resolved within the coming days.
It comes off the back of President Biden reassuring Americans yesterday the country would “not default”.
With that in mind, here are some ASX-listed companies to keep an eye on today:
MTM Critical Metals (MTM) has made a new laterite nickel discovery at the Seahorse prospect, within its East Laverton project in Western Australia.
The company received results from a recently completed aircore drilling program, which returned a highest grade intersection of 2.2 per cent nickel over one metre, and numerous other samples of greater than one per cent nickel.
“The discovery of lateritic nickel mineralisation is the successful result of MTM’s systematic exploration campaign at the Seahorse prospect over the past two years,” MTM Managing Director Lachlan Reynolds said.
Shares in MTM last traded at 14 cents.
Also in the materials space, Great Western Exploration (GTE) has completed phase one drilling at its Firebird gold project in Western Australia.
The company’s drilling efforts were designed to test the large ultrafine+ soil anomaly, not previously drilled.
GTE’s phase one program included a total of 3040 metres of aircore drilling, intersecting highly weathered Archean greenstone volcanic sediments and mafic units.
Assays are expected to be returned within eight weeks.
Shares in GTE last traded at 4.2 cents.
My Food Bag (MFB) has posted revenue figures of $175.7 million in FY23, down 9.4 per cent on FY22 on the back of a “challenging year”.
“Inflationary pressure on households and low consumer confidence have resulted in subdued demand, driving diseconomies of scale within the business,” MFB Chair Tony Carter said.
Mr Carter added that the company will “reset” the business as a result, with changes across its leadership, supply chains and brand positioning, all focused on strengthening the brand.
Shares in MFB last traded at 19 cents.
Meanwhile, Imugene (IMU) has received US Food and Drug Administration (FDA) Investigation New Drug (IND) clearance to begin a clinical study on onCARlytics.
It means IMU can start patient recruitment and dosing in a first-in-class study for the onCARlytics platform in patients with solid tumours.
“The start of our onCARlytics study, which is first-in-class, is a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers, which to date have been untreatable with CD19-targeting biological drugs,” IMU CEO and Managing Director Leslie Chong said.
Shares in IMU last traded at 11.5 cents.
Noxopharm (NOX) has revealed a new preclinical product candidate from its Sofra technology platform has been shown to reduce inflammation in autoimmune diseases.
The company reported the research demonstrates the effectiveness of both Sofra and SOF-VAC vaccine enhancer technology.
Noxopharm also announced it will present with Hudson Institute of Medical Research at the international lupus conference, allowing the company’s technology to attract greater interest globally.
Shares in NOX last traded at 4.8 cents.